Search

Your search keyword '"Berkun Y"' showing total 7 results
Start Over Author "Berkun Y" Topic autoimmune diseases
7 results on '"Berkun Y"'

1. Update on Auto-Inflammatory Diseases and Familial Mediterranean Fever.

Author

Berkun Y and Eisenstein EM

Subjects
Age of Onset, Early Medical Intervention, Humans, Immunity, Innate, Mutation, Pyrin, Tubulin Modulators pharmacology, Antibodies, Monoclonal pharmacology, Autoimmune Diseases diagnosis, Colchicine pharmacology, Cytoskeletal Proteins genetics, Familial Mediterranean Fever diagnosis, Familial Mediterranean Fever drug therapy, Familial Mediterranean Fever ethnology, Familial Mediterranean Fever genetics, Familial Mediterranean Fever physiopathology, Inflammation immunology, Interleukin-1beta antagonists & inhibitors
Published
2016

2. The mosaic of autoimmunity: genetic factors involved in autoimmune diseases--2008.

Author

Shoenfeld Y, Gilburd B, Abu-Shakra M, Amital H, Barzilai O, Berkun Y, Blank M, Zandman-Goddard G, Katz U, Krause I, Langevitz P, Levy Y, Orbach H, Pordeus V, Ram M, Sherer Y, Toubi E, and Tomer Y

Subjects
Autoantibodies blood, Haplotypes, Humans, Insulin genetics, Minisatellite Repeats genetics, Nod2 Signaling Adaptor Protein genetics, Thyroglobulin genetics, Autoimmune Diseases genetics
Published
2008

3. The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases--2008.

Author

Shoenfeld Y, Blank M, Abu-Shakra M, Amital H, Barzilai O, Berkun Y, Bizzaro N, Gilburd B, Zandman-Goddard G, Katz U, Krause I, Langevitz P, Mackay IR, Orbach H, Ram M, Sherer Y, Toubi E, and Gershwin ME

Subjects
Autoantibodies blood, Autoimmunity physiology, Desensitization, Immunologic, Humans, Immunoglobulins, Intravenous therapeutic use, Immunologic Factors therapeutic use, Liver Cirrhosis, Biliary immunology, Peptide Fragments therapeutic use, T-Lymphocytes, Regulatory drug effects, T-Lymphocytes, Regulatory physiology, Tumor Necrosis Factor-alpha antagonists & inhibitors, Autoimmune Diseases immunology, Autoimmune Diseases therapy
Published
2008

4. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases--2008.

Author

Shoenfeld Y, Zandman-Goddard G, Stojanovich L, Cutolo M, Amital H, Levy Y, Abu-Shakra M, Barzilai O, Berkun Y, Blank M, de Carvalho JF, Doria A, Gilburd B, Katz U, Krause I, Langevitz P, Orbach H, Pordeus V, Ram M, Toubi E, and Sherer Y

Subjects
Autoimmune Diseases physiopathology, Circadian Rhythm physiology, Epstein-Barr Virus Infections complications, Female, Humans, Pregnancy physiology, Smoking adverse effects, Stress, Physiological complications, Stress, Psychological complications, Vaccines adverse effects, Autoimmune Diseases etiology, Hormones physiology
Published
2008

5. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases--2008

Author

Shoenfeld, Y., Zandman Goddard, G., Stojanovich, L., Cutolo, M., Amital, H., Levy, Y., Abu Shakra, M., Barzilai, O., Berkun, Y., Blank, M., De Carvalho Jf, Andrea Doria, Gilburd, B., Katz, U., Krause, I., Langevitz, P., Orbach, H., Pordeus, V., Ram, M., Toubi, E., and Sherer, Y.

Subjects
Epstein-Barr Virus Infections, Vaccines, Pregnancy, Stress, Physiological, Smoking, Humans, Female, Hormones, Stress, Psychological, Autoimmune Diseases, Circadian Rhythm
Published
2008

6. Common infectious agents prevalence in antiphospholipid syndrome.

Author

Zinger, H., Sherer, Y., Goddard, G., Berkun, Y., Barzilai, O., Agmon-Levin1, N., Ram, M., Blank, M., Tincani, A., Rozman, B., Cervera, R., and Shoenfeld, Y.

Subjects
ANTIPHOSPHOLIPID syndrome, AUTOIMMUNE diseases, DISEASE prevalence, TOXOPLASMA, RUBELLA
Abstract

Antiphospholipid syndrome is characterized by thrombosis and pregnancy loss. Infections are generally associated with autoimmune diseases, but in the setting of antiphospholipid syndrome this link has been suggested as having a pathogenic role. In this study, 98 patients with antiphospholipid syndrome were screened for antibodies directed to several infectious agents. The main finding in this study is the significantly higher prevalence of IgM antibodies to toxoplasma and rubella. This novel finding suggests that these infections might be associated with antiphospholipid syndrome. As autoimmune diseases and, in particular, antiphospholipid syndrome are associated with infections, mainly the catastrophic type of the syndrome, this finding implies that a current infection with these agents, i.e. toxoplasma and rubella, might either be related to the pathogenesis of antiphospholipid syndrome or alternatively to its manifestations. [ABSTRACT FROM AUTHOR]

Published
2009

7. Outcome of a national Israeli cohort of pediatric systemic lupus erythematosus.

Author

Uziel, Y., Gorodnitski, N., Mukamel, M., Padeh, S., Brik, R., Barash, J., Mevorach, D., Berkun, Y., Tauber, T., Press, J., Harel, L., Navon, P., Rubenstein, M., Naparstek, Y., and Hashkes, P. J.

Subjects
SYSTEMIC lupus erythematosus, AUTOIMMUNE diseases, PEDIATRIC therapy, CHRONIC kidney failure, KIDNEY diseases, RHEUMATOLOGY, JOINT diseases
Abstract

The aim of this study was to describe the clinical manifestations and outcomes of a national cohort of childhood systemic lupus erythematosus (cSLE). All cases of cSLE registered in the Israeli national registry of children with rheumatic diseases between 1987–2003 were examined for disease activity and damage by the SLE disease activity index (SLEDAI) and SLE collaborating clinics/American College of Rheumatology (SLICC/ACR) damage index. Demographic, clinical, laboratory and treatment factors were analysed for their effect on the outcome. One-hundred and two patients were identified, 81% females, with a mean age at diagnosis of 13.3 ± 2.6 years. The mean SLEDAI score was 17.2 ± 9.0 (range 2–60). Fifty four patients were followed for at least five years. The mean SLEDAI decreased to 7.6 ± 6.3 (0–29) and the mean SLICC/ACR damage index was 0.7 ± 1.6 (0–8). Five patients developed chronic renal failure. No patients died. No factors were found to be significantly associated with the outcome except the initial SLEDAI score. The five-year outcome of our national cSLE cohort was good; with relatively low activity and minimal damage in most patients. The initial SLEDAI predicted the development of late damage. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results